CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS). There are many causes of CRS, and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need.
CytoAgents has successfully completed Phase 1 human clinical trials focused on safety
CytoAgents targets cytokines specifically active in CRS, allowing treatment without disrupting normal immune system mechanisms
CytoAgents addresses multiple areas of high unmet need related to CRS
CytoAgents’ drug enables treatments for oncology, dermatology, neurology, and respiratory/COVID to become more broadly accessible
The CytoAgents team is working on bringing to market novel treatments of the symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, commonly known as cytokine storm.Meet the Team
In the fight against Cytokine Release Syndrome, CytoAgents has been able to make great progress. After having successfully completed Phase I Human Clinical Trials , we are currently planning Phase II trials to be applicable across a number of therapeutic areas.
Join us as we transform CRS through a novel approach that allows for prevention as well as treatment.Executive Summary